Live Breaking News & Updates on Mdma Assisted Psychotherapy

Stay updated with breaking news from Mdma assisted psychotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Why the TGA should reschedule MDMA and psilocybin for the treatment of mental illness

The Therapeutic Goods Administration (TGA) is considering rescheduling psilocybin and MDMA from their current classification as Schedule 9 prohibited substances to Schedule 8 controlled substances.
This would allow psychiatrists to use these drugs in combination with psychotherapy for the treatment of conditions such as depression and post-traumatic stress disorder (PTSD).
Here’s why we believe that would be a good idea.
A bit of background
On February 3, the TGA announced an interim decision to retain psilocybin and MDMA as Schedule 9 drugs.
The TGA cited limited evidence of therapeutic benefit, safety concerns, potential for abuse, and lack of suitably trained psychiatrists.
But the final ruling, which was expected on April 22, has now been delayed while the TGA seek independent expert advice on the “therapeutic value, risks, and benefits to public health” of the change. ....

South Australia , United States , City Of , United Kingdom , Johns Hopkins University , Monash University , Imperial College London , Therapeutic Goods Administration , Imperial College , Mdma Assisted Psychotherapy , Mental Health , Mental Illness , Psychedelic Drugs , தெற்கு ஆஸ்திரேலியா , ஒன்றுபட்டது மாநிலங்களில் , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , ஜான்ஸ் ஹாப்கின்ஸ் பல்கலைக்கழகம் , மோனாஷ் பல்கலைக்கழகம் , ஏகாதிபத்தியம் கல்லூரி லண்டன் , ஏகாதிபத்தியம் கல்லூரி ,

Will Australia legalise ecstasy and magic mushrooms to treat mental illness? Here's why it's still too soon

Disclosure statement
Stephen Bright is a Director of the DGR-1 charity, Psychedelic Research in Science & Medicine Ltd (PRISM). Stephen Bright has had no formal association with Mind Medicine Australia, except through its allocated funding of PRISM s support of clinical research at St Vincent s Hospital Melbourne.
Martin Williams is Executive Director of the DGR-1 charity, Psychedelic Research in Science & Medicine Ltd (PRISM), and receives fellowship funding from the Vasudhara Foundation. Martin Williams previously consulted to Mind Medicine Australia (MMA) as Scientific Officer, from 1 April 2019 to 31 March 2020. PRISM received tax-deductible donations from MMA in March and November 2019, allocated entirely to the first year of the St Vincent s Hospital Melbourne clinical trial of psilocybin-assisted therapy for anxiety and depression associated with terminal illness. Martin Williams resigned from the role of Scientific Officer with MMA on 4 April 2020, and PRISM termin ....

South Australia , New South Wales , Monash University , University Of Melbourne , Edith Cowan University , Therapeutic Goods Administration , Mind Medicine Australia , Jonathon Carmichael , Cowan University , Weekly Dose , Pharmaceutical Benefits , Mdma Assisted Psychotherapy , Magic Mushrooms , Mental Illness , தெற்கு ஆஸ்திரேலியா , புதியது தெற்கு வேல்ஸ் , மோனாஷ் பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் மெல்போர்ன் , எடித் கோவன் பல்கலைக்கழகம் , மனம் மருந்து ஆஸ்திரேலியா , ஜொனாதன் கார்மைக்கேல் , கோவன் பல்கலைக்கழகம் , வாராந்திர டோஸ் , மருந்து நன்மைகள் , மந்திரம் காளான்கள் , மன உடல் நலமின்மை ,